Silexion Therapeutics Corp Ordinary Shares
Symbol: SLXN (NASDAQ)
Company Description:
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
- Today's Open: $3.665
- Today's High: $3.699
- Today's Low: $3.62
- Today's Volume: 8
- Yesterday Close: $3.64
- Yesterday High: $3.65
- Yesterday Low: $3.52
- Yesterday Volume: 55.85K
- Last Min Volume: 1
- Last Min High: $3.645
- Last Min Low: $3.645
- Last Min VWAP: $3.645
- Name: Silexion Therapeutics Corp Ordinary Shares
- Website: https://silexion.com
- Listed Date: 2024-08-16
- Location: RAMAT GAN, L3
- Market Status: Active
- CIK Number: 0002022416
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $11.38M
- Round Lot: 100
- Outstanding Shares: 3.13M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-30 | EFFECT | View |
| 2025-09-30 | 8-K | View |
| 2025-09-26 | S-3 | View |
| 2025-09-26 | 8-K | View |
| 2025-09-25 | 8-K | View |
| 2025-09-23 | SCHEDULE 13D/A | View |
| 2025-09-18 | SCHEDULE 13G | View |
| 2025-09-17 | SCHEDULE 13G | View |
| 2025-09-15 | SCHEDULE 13G/A | View |
| 2025-09-15 | SCHEDULE 13G | View |
| 2025-09-15 | 8-K | View |
| 2025-09-15 | SCHEDULE 13G | View |
| 2025-09-12 | 8-K | View |
| 2025-09-12 | 424B4 | View |
| 2025-09-11 | EFFECT | View |
| 2025-09-11 | 8-K | View |
| 2025-09-05 | S-1 | View |
| 2025-09-04 | EFFECT | View |
| 2025-09-04 | 8-K | View |
| 2025-09-04 | 424B3 | View |